2024-09-27 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance Overview**

Merck & Co Inc (MRK) is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

* **Cumulative Return:** MRK has yielded a cumulative return of 78.61%, lagging behind the S&P 500 (VOO) which has returned 133.29%.
* **Relative Performance:** The current relative divergence is -54.68, indicating that MRK has underperformed the S&P 500 by approximately 54.68%. This places its relative performance at the 29.35th percentile of its historical range.

**2. Recent Price Action**

* **Closing Price:** $114.73
* **5-day Moving Average:** $115.98
* **20-day Moving Average:** $116.66
* **60-day Moving Average:** $118.92

The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a potential downtrend.

**3. Technical Indicators**

* **RSI (Relative Strength Index):** 33.56. The RSI suggests that MRK is in oversold territory, but it is important to note that this indicator alone cannot predict future price movement.
* **PPO (Percentage Price Oscillator):** -0.07. A negative PPO value suggests that the stock's price is declining relative to its moving averages.
* **Delta_Previous_Relative_Divergence:** -6.19. The negative value indicates that MRK's relative divergence has been decreasing recently, potentially suggesting a short-term downtrend.
* **Expected Return:** 0.0%. This represents the estimated maximum potential return on investment over the next 5 years.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

**Most Recent Earnings (2024-08-05):** 
* **EPS:** $2.15. The company exceeded analysts' expectations for earnings per share, which were at $1.98.
* **Revenue:** $16.11 Billion. The company's revenue slightly surpassed analysts' expectations of $16.07 Billion.

**5. News and Recent Issues**

According to FINBOLD, recent market outlook for MRK is relatively positive. 
* Several analysts have maintained a "Buy" rating on the stock, citing potential growth in its key markets.
* **Key highlights:**
    * Strong performance of Keytruda, a leading cancer immunotherapy drug, continues to drive the company's growth.
    * The company's pipeline includes several promising drug candidates in various therapeutic areas, particularly in oncology and immunology.
    * MRK's focus on R&D and its commitment to developing innovative medicines position it for long-term growth.

**6. Comprehensive Analysis**

MRK's recent performance has lagged behind the S&P 500. However, the company continues to be a strong performer in the pharmaceutical industry, with a focus on innovation and strong growth in its key markets. While the stock is currently trading below its moving averages, some analysts believe that it has strong growth potential due to its expanding pipeline and market-leading drugs. 

**7. Conclusion**

MRK's future performance will depend on factors such as the continued success of its existing products, the development of new products, and the overall market environment. However, the company's strong track record, R&D focus, and promising pipeline suggest that it is well-positioned for long-term growth. Investors looking for exposure to the pharmaceutical sector may want to consider MRK as a potential investment, taking into consideration its current technical indicators and market outlook. 
